| Migraines? These dietary supplements may help
|
2004-06-01 Jane E. Allen, The Los Angeles Times
For
years, Joan Rozen lived on Excedrin pills, too busy as a mother and
teacher to bow to daily migraine headaches.
"Sometimes
they would get so intense I would get nauseated, but I just had to
keep going," said Rozen, 60, of Binghamton, N.Y.
A
couple of years ago her son Todd, a neurologist, suggested that
coenzyme Q10, a dietary supplement he'd studied for migraine
prevention, might break her dependence on the aspirin-based pills.
She began taking 150 milligrams daily and was told the medication
could take a few months to work.
Then,
one day, "I realized I wasn't getting these daily headaches,"
Rozen said. "I cannot tell you what a tremendous difference it
has made in my life."
Coenzyme
Q10 is among dietary supplements showing promise in preventing or
reducing the severity of migraines suffered by an estimated 28
million Americans.
Often
preceded by flashing lights or other visual disturbances, the
potentially disabling headaches are often unstoppable, sending
sufferers retreating into quiet, dark rooms. Powerful drugs called
triptans have proven effective at aborting migraines, but patients
want a way to avert the attacks.
Daily
doses of some prescription blood pressure drugs, antidepressants and
anti-seizure drugs can be taken as preventives, but have significant
side effects and don't help everyone.
As
a result, a growing number of patients, heartened by emerging
research, are embracing prevention using relatively inexpensive
over-the-counter dietary supplements, which have few side effects.
"The
bottom line is that there are safe alternatives with a firm
scientific basis for preventing migraine for people who don't want to
take prescription drugs, that also can be used to complement
prescription drugs," said Dr. Richard B. Lipton, a neurology
professor at Albert Einstein College of Medicine in the Bronx, N.Y.
They
include:
Coenzyme
Q10:
Dr. Todd Rozen, a headache specialist at the Michigan
Head Pain & Neurological Institute
in Ann Arbor, conducted early research demonstrating CoQ10's
potential to prevent migraines. Because some migraines have been
associated with a deficiency in cells' ability to generate energy,
Rozen thought it made sense to test a compound important to the
functioning of cells' batteries, the mitochondria. Swiss researchers
reported April 28 at the American Academy of Neurology's annual
meeting that 300 milligrams daily halved the incidence of migraines,
compared with dummy pills.
"I
certainly wouldn't hesitate to put patients on it," said Dr.
Robert B. Daroff, a neurology professor at Case Western Reserve
University School of Medicine in Cleveland, and current president of
the American
Headache Society.
Magnesium:
Several studies have shown that magnesium prevents migraines in about
half of cases. Dr. Alexander Mauskop, director of the New York
Headache Center, who has long studied magnesium, believes about 50
percent of migraine patients have an underlying magnesium deficiency.
Recommended doses range from 360 milligrams to 1 gram. Magnesium can
cause diarrhea if taken on an empty stomach and should be taken with
nondairy meals because it interferes with calcium absorption. It
shouldn't be used by people with serious kidney problems.
Riboflavin:
Also called vitamin B-2, it's been shown in several studies to work
better than a placebo in the prevention of migraines. The usual dose
is 400 milligrams. Riboflavin acts on energy production within
mitochondria.
Feverfew:
This
herbal relative of the daisy may prevent some of the blood vessel
dilation associated with migraine pain. One major caution: Feverfew
can interact with Coumadin and other blood thinners.
Magnesium-riboflavin-feverfew
combinations:
Sold under the brand names MigreLief and MigraHealth, two pills pack
300 milligrams of magnesium, 400 milligrams of riboflavin and 100
milligrams of feverfew.
Butterbur
root extract:
Sold under the brand name Petadolex, the soft gel tablets have been
shown in several studies, including one published in the February
issue of the journal European Neurology, to halve migraine frequency.
|